Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brilaroxazine - Reviva Pharmaceuticals

Drug Profile

Brilaroxazine - Reviva Pharmaceuticals

Alternative Names: brilaroxazine lipogel; RP 5000; RP-5063

Latest Information Update: 27 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Reviva Pharmaceuticals
  • Class Antidepressants; Antifibrotics; Antipsychotics; Behavioural disorder therapies; Benzoxazines; Chlorobenzenes; Ethers; Ketones; Mood stabilisers; Piperazines; Small molecules
  • Mechanism of Action Dopamine D2 receptor partial agonists; Dopamine D3 receptor partial agonists; Dopamine D4 receptor partial agonists; Serotonin 1A receptor partial agonists; Serotonin 2A receptor partial agonists; Serotonin 6 receptor antagonists; Serotonin 7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Schizophrenia
  • Phase II Schizoaffective disorder
  • Phase I Idiopathic pulmonary fibrosis; Pulmonary arterial hypertension
  • Preclinical Psoriasis
  • No development reported Attention-deficit hyperactivity disorder; Bipolar disorders; Major depressive disorder; Psychotic disorders
  • Discontinued Autistic disorder; Gilles de la Tourette's syndrome

Most Recent Events

  • 27 Sep 2023 Reviva Pharmaceuticals has patent protection for treatment of pulmonary fibrosis in Japan (JP 734 391 0B2)
  • 17 Aug 2023 Reviva Pharmaceuticals completes enrolment in the phase III RECOVER trial for Schizophrenia (In adults, In the elderly) in USA, Asia, Bulgaria (PO) (NCT05184335) (EudraCT2021-004193-64)
  • 19 Jul 2023 Interim pharmacodynamics data from a preclinical studies in idiopathic pulmonary fibrosis presented at the 119th International Conference of the American Thoracic Society (ATS-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top